1. The 'Scope' of Post-ERCP Pancreatitis
- Author
-
Parth J. Parekh, Sanjay K. Sikka, Raj Majithia, and Todd H. Baron
- Subjects
Male ,medicine.medical_specialty ,Psychological intervention ,Chemoprevention ,03 medical and health sciences ,0302 clinical medicine ,Age Distribution ,Risk Factors ,Medicine ,Humans ,Sex Distribution ,Intensive care medicine ,Adverse effect ,Cholangiopancreatography, Endoscopic Retrograde ,Endoscopic retrograde cholangiopancreatography ,medicine.diagnostic_test ,business.industry ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Surgery ,Review article ,Pancreatitis ,030220 oncology & carcinogenesis ,Relative risk ,Number needed to treat ,030211 gastroenterology & hepatology ,Female ,business - Abstract
Pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography, with the potential for clinically significant morbidity and mortality. Several patient and procedural risk factors have been identified that increase the risk of post–endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Considerable research efforts have identified several pharmacologic and procedural interventions that can drastically affect the incidence of PEP. This review article addresses the underlying mechanisms at play for the development of PEP, identifying patient and procedural risk factors and meaningful use of risk-stratification information, and details current interventions aimed at reducing the risk of this complication.
- Published
- 2016